Brand-name companies responded to the complaints, saying that the generic companies aren’t authorized to buy drugs under the federal drug-safety program. The generic companies say that they are just trying to block competition.
Brand-name drugs get an extended period of exclusivity on the market due to their patents or other legal protections. Before that period expires, generic companies can buy the product in bulk from the brand-name maker so they can develop a copycat version to sell once the exclusivity period is over.
The drug-safety program addressed by the brand-name companies was developed in 2007 and restricts distribution of some powerful pharmaceuticals to combat misuse.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
